

## 8. Literaturverzeichnis

1. Adelman JU, Von Seggern R. Cost considerations in headache treatment. Part 1: Prophylactic migraine treatment. *Headache* 35: 479-487, 1995.
2. al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. *Cephalalgia* 13: 128-131, 1993.
3. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. *Headache* 29: 215-218, 1989.
4. Andersson KE, Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. *Drugs* 39: 355-373, 1990.
5. Anthony M, Hinterberger H, Lance JW. Plasma sodium valproate levels and clinical response in epilepsy. In: 14 ed. p. 208, 1977.
6. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. *Headache* 30: 710-715, 1990.
7. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D, for the MIGR-002 Study Group. Topiramate for migraine prevention. A randomized controlled trial. *JAMA* 291: 965-973, 2004.
8. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. *Cephalalgia* 17: 93-100, 1997.
9. Diener et al: Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. *J Neurol* 251: 943-50, 2004.
10. Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT<sub>1B/1D</sub> agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. *Cephalalgia* 17 Suppl 18: 41-52, 1997.
11. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. *Neurology* 58: 1652 – 1659, 2002
12. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. *Can J Neurol Sci* 19: 340-345, 1992.

13. Grottemeyer KH, Scharafinski HW, Schlake HP, Husstedt IW. Acetylsalicylic acid vs. metoprolol in migraine prophylaxis - a double-blind cross-over study. *Headache* 30: 639-641, 1990.
14. Havanka Kannianen H, Hokkanen E, Myllyla VV. Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. *Headache* 28: 607-611, 1988.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 8, Suppl.7: 1-93, 1988.
16. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. *Cephalalgia* 12: 81-84, 1992.
17. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. *Headache* 31: 333-340, 1991.
18. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. *Neurology* 44: 647-651, 1994.
19. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. *Arch Neurol* 54: 1141-1145, 1997.
20. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhäupl KM, Arnold G. Valproic Acid is effective in Migraine prophylaxis at low serum levels: A Prospective open-label study. *Headache*; 41: 774-778, 2001.
21. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. *Cephalalgia* 17: 103-108, 1997.
22. Lenaerts M, Bastings E, Sianard J, Schoenen J. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. *Acta Neurol Belg* 96: 126-129, 1996.
23. Lipton RB, Stewart WF. Clinical applications of zolmitriptan (Zomig, 311C90). *Cephalalgia* 17 Suppl 18: 53-59, 1997.
24. Martinez Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. *Cephalalgia* Suppl 8: 15-20, 1988.
25. Massiou H, Bousser MG. Beta-blockers and migraine. *Pathol Biol Paris* 40: 373-380, 1992.
26. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An Open Label Study. *Headache* 31: 71-74, 1991.

27. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. *Arch Neurol* 52: 281-286, 1995.
28. May T, Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. In: 7 ed. p. 387, 1985.
29. Michel P, Pariente P, Duru G, Dreyfuss JP, Chabriat H, Henry P. MIG ACCESS: a population-based, nationwide, comparative survey of access to care in migraine in France. *Cephalalgia* 16: 50-55, 1996.
30. Montastruc JL, Senard JM. Calcium channel blockers and prevention of migraine. *Pathol Biol (Paris)* 40: 381-388, 1992.
31. Nutt JG, Kupferberg HJ. Linear relationship between plasma concentration and dosage of sodium valproate. In: 20 ed. p. 589, 1979.
32. Olesen J. Cerebral blood flow in migraine with aura. *Pathol Biol (Paris)* 40(4): 318-324, 1992.
33. Olesen J.: The international classification of headache disorders. 2nd edition (ICHD-II). *Rev Neurol (Paris)* 161(6-7):689-91, 2005.
34. Pradalier A, Serratrice G, Collard M, Hirsch E, Fève J, Masson M, Masson C, Dry J, Koulikovsky G, Nguyen G, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. *Cephalalgia* 9: 247-253, 1989.
35. Rothrock JF, Kelly NM, Brody ML, Golbeck A. A differential response to treatment with divalproex sodium in patients with intractable headache, see comments. *Cephalalgia* 14: 241-244, 1994.
36. Schoenen J, Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT<sub>1B/1D</sub> agonist: an overview of efficacy. *Cephalalgia Suppl* 18: 28-40, 1997.
37. Seshia SS, Wolstein JR. International Headache Society classification and diagnostic criteria in children: a proposal for revision. *Dev Med Child Neurol* 37: 879-882, 1995.
38. Sørensen KV. Valproate: a new drug in migraine prophylaxis. *Acta Neurol Scand* 78: 346-348, 1988.
39. Vajda FJ, Milhaly GW, Miles JL, Morris PM, Bladin PF. Sodium valproate: dose-plasma level relationships and interdose fluctuations. In: 15 ed. p. 145, 1978.

40. van de Ven LLM, Franke CL, Koehler PJ, on behalf of the Investigators. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. *Cephalalgia* 17: 596-599, 1997.
41. Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. *Neurology* 35: 1304-1310, 1985.
42. Wober C, Wober Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. *Cephalalgia* 11: 251-256, 1991.
43. Wober-Bingol C, Wober C, Wagner-Ennsgraber C, Karwautz A, Vesely C, Zebenhoizer K, Geldner J. IHS criteria for migraine and tension-type headache in children and adolescents. *Headache* 36: 231-238, 1996.
44. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. *Arch Neurol* 42: 582-584, 1985.